Efficacy and safety of dovitinib in pretreated patients with advanced squamous non‐small cell lung cancer with <i>FGFR1</i> amplification: A single‐arm, phase 2 study

Abstract

Treatment with dovitinib demonstrated modest efficacy in patients with advanced SCC with FGFR1 amplification. Further studies to evaluate other biomarkers correlated with the efficacy of dovitinib in patients with SCC are warranted. Cancer 2016;122:3024-3031. © 2016 American Cancer Society.